Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEXA M HETZEL

Physician Assistants & Advanced Practice Nursing Providers Physician Assistant

NPI
1851887301
CMS profile
10806017
Location
EAST WINDSOR, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$74,013.53

331 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 7; records 101–150 of 331 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEXA M HETZEL

NPI 1851887301 · CMS profile ID 10806017

Physician Assistants & Advanced Practice Nursing Providers / Physician Assistant

EAST WINDSOR, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 7; records 101–150 of 331 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851887301?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEXA M HETZEL, NPI 1851887301, CMS profile ID 10806017. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 331 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851887301?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ALEXA M HETZEL, NPI 1851887301, CMS profile ID 10806017. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 331 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851887301?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ALEXA M HETZEL, NPI 1851887301, CMS profile ID 10806017, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 331 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1851887301?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

331 matching records · $74,013.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 331 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 331.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $29.7410/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886207081 CMS
Janssen Biotech, Inc. $13.6210/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886207075 CMS
LEO Pharma Inc. $15.0210/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936348653 CMS
LEO Pharma Inc. $1.3610/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936348659 CMS
ABBVIE INC. $1,125.0010/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999921 CMS
ABBVIE INC. $12.0010/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999919 CMS
Janssen Biotech, Inc. $15.1510/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886207069 CMS
ABBVIE INC. $14.2910/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999917 CMS
Lilly USA, LLC $14.2710/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918376925 CMS
ABBVIE INC. $34.1210/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999915 CMS
E.R. Squibb & Sons, L.L.C. $3.7210/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608443 CMS
E.R. Squibb & Sons, L.L.C. $13.2410/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608445 CMS
Janssen Biotech, Inc. $12.6610/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886207065 CMS
Janssen Biotech, Inc. $23.9010/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886207319 CMS
ABBVIE INC. $14.9510/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999913 CMS
MAYNE PHARMA INC. $15.9510/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959900653 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $11.7710/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947516501 CMS
ABBVIE INC. $104.4510/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999911 CMS
E.R. Squibb & Sons, L.L.C. $843.0010/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608451 CMS
E.R. Squibb & Sons, L.L.C. $2,400.0010/03/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608517 CMS
Incyte Corporation $765.0010/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942968211 CMS
ABBVIE INC. $26.3510/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999897 CMS
ABBVIE INC. $454.2010/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999899 CMS
ABBVIE INC. $38.5410/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999901 CMS
ABBVIE INC. $80.6910/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999903 CMS
ABBVIE INC. $37.3310/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999905 CMS
ABBVIE INC. $2.9610/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999907 CMS
ABBVIE INC. $73.4710/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999909 CMS
ABBVIE INC. $215.4609/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999891 CMS
ABBVIE INC. $161.0309/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999893 CMS
ABBVIE INC. $122.5909/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999895 CMS
Janssen Biotech, Inc. $14.3309/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886207393 CMS
E.R. Squibb & Sons, L.L.C. $15.8109/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608447 CMS
Janssen Biotech, Inc. $12.7909/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886207059 CMS
Sun Pharmaceutical Industries Inc. $19.1809/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947962129 CMS
ABBVIE INC. $14.2509/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999889 CMS
E.R. Squibb & Sons, L.L.C. $14.0109/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608439 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $13.3609/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947516495 CMS
LEO Pharma Inc. $15.1709/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936348647 CMS
ABBVIE INC. $1,125.0009/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999887 CMS
E.R. Squibb & Sons, L.L.C. $25.4109/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608457 CMS
E.R. Squibb & Sons, L.L.C. $124.9909/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608519 CMS
E.R. Squibb & Sons, L.L.C. $49.9909/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608521 CMS
E.R. Squibb & Sons, L.L.C. $59.9909/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608523 CMS
E.R. Squibb & Sons, L.L.C. $29.9509/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608525 CMS
E.R. Squibb & Sons, L.L.C. $349.8509/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608527 CMS
E.R. Squibb & Sons, L.L.C. $315.4709/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932608529 CMS
E.R. Squibb & Sons, L.L.C. $29.9409/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965113331 CMS
ABBVIE INC. $81.1509/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891999885 CMS
Janssen Scientific Affairs, LLC $145.6209/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887235185 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $18,725.81 171
PY2022 $74,013.53 331
PY2023 $115,751.66 422
PY2024 $130,968.12 435
PY2025 $248,290.61 568

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $162,358.13 18

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

18 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $398.75 12/25/2025 Non-covered Recipient Entity
WINDSOR DERMATOLOGY PC
A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS No dispute reported 06/30/2026 1184280314
Principal investigator 1 Janssen Research & Development, LLC $4,537.00 12/22/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175432965
Principal investigator 1 Janssen Research & Development, LLC $8,960.00 12/19/2025 Non-covered Recipient Entity
SDG DERMATOLOGY PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175432958
Principal investigator 1 SANOFI US SERVICES INC. $3,309.00 12/10/2025 Non-covered Recipient Entity
Sdg Dermatology Pc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103929
Principal investigator 1 SANOFI US SERVICES INC. $8,243.00 12/04/2025 Non-covered Recipient Entity
Sdg Dermatology Pc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103903
Principal investigator 1 SANOFI US SERVICES INC. $10,824.20 11/14/2025 Non-covered Recipient Entity
Sdg Dermatology Pc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226103896
Principal investigator 1 Janssen Research & Development, LLC $17,781.00 10/23/2025 Non-covered Recipient Entity
Schweiger Derm Group-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244320
Principal investigator 1 SANOFI US SERVICES INC. $6,981.00 10/22/2025 Non-covered Recipient Entity
Sdg Dermatology Pc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103870
Principal investigator 1 SANOFI US SERVICES INC. $8,696.00 09/17/2025 Non-covered Recipient Entity
Sdg Dermatology Pc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103827
Principal investigator 1 SANOFI US SERVICES INC. $24,706.00 08/20/2025 Non-covered Recipient Entity
Sdg Dermatology Pc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103786
Principal investigator 1 Janssen Research & Development, LLC $10,668.60 07/31/2025 Non-covered Recipient Entity
Schweiger Derm and Allergy-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244310
Principal investigator 1 Janssen Research & Development, LLC $18,966.40 07/31/2025 Non-covered Recipient Entity
Schweiger Derm Group-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244336
Principal investigator 1 Janssen Research & Development, LLC $45.00 07/31/2025 Non-covered Recipient Entity
Schweiger Derm and Allergy-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244367
Principal investigator 1 Janssen Research & Development, LLC $2,963.50 07/22/2025 Non-covered Recipient Entity
Schweiger Derm and Allergy-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244328
Principal investigator 1 Janssen Research & Development, LLC $2,327.88 07/22/2025 Non-covered Recipient Entity
Schweiger Derm and Allergy-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244383
Principal investigator 1 Eli Lilly and Company $18,080.00 07/08/2025 Non-covered Recipient Entity
JERRY BAGEL MD LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187885378
Principal investigator 1 SANOFI US SERVICES INC. $12,500.00 06/13/2025 Non-covered Recipient Entity
Sdg Dermatology Pc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226103718
Principal investigator 1 Janssen Research & Development, LLC $2,370.80 05/02/2025 Non-covered Recipient Entity
Schweiger Derm Group-East Windsor
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175244396